149965-40-2

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-chlorobenzyl alcohol is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a versatile building block for the development of new drugs with potential applications in treating various medical conditions.
Used in Chemical Synthesis:
In the field of organic chemistry, 5-bromo-2-chlorobenzyl alcohol serves as a valuable precursor for the synthesis of a wide range of organic compounds. Its reactive bromine and chlorine atoms can be used in various chemical reactions, such as substitution, addition, and elimination, to produce a diverse array of products.
Used in Material Science:
5-Bromo-2-chlorobenzyl alcohol can be utilized in the development of novel materials with specific properties. Its incorporation into polymers or other materials can lead to enhanced characteristics, such as improved thermal stability, chemical resistance, or mechanical strength.
Used in Research and Development:
As a chemical compound with distinct structural features, 5-bromo-2-chlorobenzyl alcohol is employed in research and development for the exploration of new chemical reactions, mechanisms, and applications. It can be used as a model compound to study the effects of halogen substitution on the reactivity and properties of benzyl alcohol derivatives.
Used in Analytical Chemistry:
5-Bromo-2-chlorobenzyl alcohol can be used as a reference material or standard in analytical chemistry for the calibration of instruments, validation of analytical methods, or the determination of the purity of related compounds. Its distinct chemical properties make it suitable for various analytical techniques, such as chromatography, spectroscopy, or titration.

InChI:InChI=1/C7H6BrClO/c8-6-1-2-7(9)5(3-6)4-10/h1-3,10H,4H2

Upstream product

• 89-98-5 2-chloro-benzaldehyde 
• 189628-37-3 2-chloro-5-bromobenzaldehyde 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 251085-87-7 methyl 5-bromo-2-chloro-benzoate 
• 42860-02-6 3‐bromo‐5‐chlorobenzoic acid 
• 76008-73-6 5-Bromo-2-chloro-benzoic acid ethyl ester 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 

Downstream Products

• 681135-28-4 5-bromo-2-chloro-(1-benzyloxymethyl)phenyl 
• 681135-29-5 5-bromo-2-chloro-(1-methoxymethyl)phenyl 
• 1225430-36-3 (5-bromo-2-chlorobenzyloxy)triisopropylsilane 
• 1416165-45-1 (1R,2S,3S,4R,5S)-1-(acetoxymethyl)-5-(3-(bromomethyl)-4-chlorophenyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triyl triacetate 
• 461432-23-5 4-bromo-1-chloro-2-[(4-ethoxyphenyl)methyl]benzene 
• 714269-57-5 (2S,3R,4S,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)-2-methoxy-tetrahydropyran-3,4,5-triol 
• 461432-26-8 dapagliflozin 
• 946001-21-4 (4-chloro-3-formyl-benzyl)-carbamic acid methyl ester 

Relevant academic research and scientific papers

Continuous-Flow Amide and Ester Reductions Using Neat Borane Dimethylsulfide Complex

Reductions of amides and esters are of critical importance in synthetic chemistry, and there are numerous protocols for executing these transformations employing traditional batch conditions. Notably, strategies based on flow chemistry, especially for amide reductions, are much less explored. Herein, a simple process was developed in which neat borane dimethylsulfide complex (BH3?DMS) was used to reduce various esters and amides under continuous-flow conditions. Taking advantage of the solvent-free nature of the commercially available borane reagent, high substrate concentrations were realized, allowing outstanding productivity and a significant reduction in E-factors. In addition, with carefully optimized short residence times, the corresponding alcohols and amines were obtained in high selectivity and high yields. The synthetic utility of the inexpensive and easily implemented flow protocol was further corroborated by multigram-scale syntheses of pharmaceutically relevant products. Owing to its beneficial features, including low solvent and reducing agent consumption, high selectivity, simplicity, and inherent scalability, the present process demonstrates fewer environmental concerns than most typical batch reductions using metal hydrides as reducing agents.

SGLTS INHIBITOR AND APPLICATION THEREOF

A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof

3-OXO-1,4-DIAZEPINYLE COMPOUNDS AS NRF2 ACTIVATORS

The present invention relates to bisaryl lactam compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the compounds of this invention include a compound of Formula (I):

BISARYL AMIDES AS NRF2 REGULATORS

The present invention relates to bisaryl amide analogs, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I).

C-triaryl glucoside compound, preparation method and application of C-triaryl glucoside compound

The invention discloses a C-triaryl glucoside compound with the structure shown in the formula I as shown in the description, or an optical isomer thereof, or pharmaceutically acceptable salt, co-crystallization composite, hydrate, solvate or prodrug molecule thereof. The compound disclosed by the invention has a very good selective inhibition effect on SGLT-2, has an obvious promotion effect on releasing of animal urine sugar, can effectively reduce blood glucose and meanwhile cannot result in the risks of weight increase, hypoglycemia and the like. The compound disclosed by the invention haslittle influence on the activity of SGLT-1 while effectively inhibiting the activity of SGLT-2, can be expected that the toxicity is low when being developed into drugs, and has obvious medication advantage.

Dapagliflozin preparation method

The invention relates to a Dapagliflozin preparation method, which comprises the following steps: using 2-chlorobenzaldehyde as a starting material, carrying out bromination, reducing, chlorinating tosynthesize 5-bromo-2-chlorobenzyl chloride, carrying out Friedel-Crafts alkylation reaction between 5-bromo-2-chlorobenzyl chloride and phenetole to synthesize 5-bromo-2-chloro-4'-ethyoxyldiphenylmethane, conducting condensation between 5-bromo-2-chloro-4'-ethyoxyldiphenylmethane and 2,3,4,6-tetra-O-trimethylsilyl-D-glucolactone, carrying out trimethylsilyl deprotection, conducting etherification, and reducing for demethylation to obtain a hypoglycemic drug Dapagliflozin. The invention has the following advantages: according to the Dapagliflozin preparation method, 2-chlorobenzaldehyde, whichis used as a starting material, is cheaper and easily available in comparison with 5-bromo-2-chlorobenzoic acid, and the technology is easy for industrialization; during the synthetic process, no rawmaterials which cause severe toxicity will be used and furthermore there is no dangerous process; the synthetic route is short and novel and the operation is simple; and through the synthetic route,purity of the final product can be raised, and the purity can reach 99% and above.

Preparation method of empagliflozin

The invention relates to a preparation method of empagliflozin. The preparation method of empagliflozin comprises the following steps: taking 2-chlorobenzaldehyde as a starting material; carrying outbromination reaction, reduction reaction and halogenating reaction on the starting material, and carrying out Friedel-Crafts alkylation reaction on the starting material and (S)-3-phenoxyl tetrahydrofuran to obtain an intermediate which is (S)-3-(4-(5-bromo-2-chlorobenzyl) phenoxyl) tetrahydrofuran; and then carrying out condensation, etherification and methoxyl removal on the intermediate and 2,3,4,6-quadri-O-trimethylsilyl-D-glucolactone to obtain the empagliflozin as a hypoglycemic drug. The preparation method of the empagliflozin has the advantages that compared with an existing synthesisprocess, the preparation method of the empagliflozin takes the 2-chlorobenzaldehyde as the starting material, raw materials are cheap and easy to obtain, industrialization is easy to implement in theprocess, the synthesis route is short, and the method is easy to operate; in a preparation process, various temperature conditions are easy to control, reaction conversion rate is high, and the totalyield can be 75% or above; and moreover, by the preparation method, the product cannot be isomerized easily, impurities are fewer, the purity of the product can be improved, and the purity can be 99%or above.

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synt

C - aryl glucoside derivative and its preparation method and use thereof

The invention discloses a C-aryl glucoside derivative shown in the general formula (I) (refer to the Specification), as well as a preparation method and application thereof, wherein R1 and R2 are defined in the Specification. The C-aryl glucoside derivati

NRF2 REGULATORS

Provided are aryl analogs，pharmaceutical compositions containing them and their use as NRF2 regulators.